Literature DB >> 26392192

Unlocking ATP13A2/PARK9 activity.

Shaun Martin1, Tine Holemans1, Peter Vangheluwe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26392192      PMCID： PMC4825597          DOI： 10.1080/15384101.2015.1093420

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  A critical role of mitochondrial phosphatase Ptpmt1 in embryogenesis reveals a mitochondrial metabolic stress-induced differentiation checkpoint in embryonic stem cells.

Authors:  Jinhua Shen; Xia Liu; Wen-Mei Yu; Jie Liu; Milou Groot Nibbelink; Caiying Guo; Toren Finkel; Cheng-Kui Qu
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

2.  Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.

Authors:  Marija Usenovic; Adam L Knight; Arpita Ray; Victoria Wong; Kevin R Brown; Guy A Caldwell; Kim A Caldwell; Igor Stagljar; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2012-05-29       Impact factor: 6.150

3.  A lipid switch unlocks Parkinson's disease-associated ATP13A2.

Authors:  Tine Holemans; Danny Mollerup Sørensen; Sarah van Veen; Shaun Martin; Diane Hermans; Gerdi Christine Kemmer; Chris Van den Haute; Veerle Baekelandt; Thomas Günther Pomorski; Patrizia Agostinis; Frank Wuytack; Michael Palmgren; Jan Eggermont; Peter Vangheluwe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-01       Impact factor: 11.205

4.  The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity.

Authors:  Débora E Rinaldi; Gerardo R Corradi; Lucía Martínez Cuesta; Hugo P Adamo; Felicitas de Tezanos Pinto
Journal:  Biochim Biophys Acta       Date:  2015-04-23

5.  Phosphatidic acid (PA)-preferring phospholipase A1 regulates mitochondrial dynamics.

Authors:  Takashi Baba; Yuriko Kashiwagi; Nagisa Arimitsu; Takeshi Kogure; Ayumi Edo; Tomohiro Maruyama; Kazuki Nakao; Hiroki Nakanishi; Makoto Kinoshita; Michael A Frohman; Akitsugu Yamamoto; Katsuko Tani
Journal:  J Biol Chem       Date:  2014-03-05       Impact factor: 5.157

Review 6.  Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders.

Authors:  Sarah van Veen; Danny M Sørensen; Tine Holemans; Henrik W Holen; Michael G Palmgren; Peter Vangheluwe
Journal:  Front Mol Neurosci       Date:  2014-05-27       Impact factor: 5.639
  6 in total
  6 in total

1.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

2.  Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

Authors:  Alejandro Estrada-Cuzcano; Shaun Martin; Teodora Chamova; Matthis Synofzik; Dagmar Timmann; Tine Holemans; Albena Andreeva; Jennifer Reichbauer; Riet De Rycke; Dae-In Chang; Sarah van Veen; Jean Samuel; Ludger Schöls; Thorsten Pöppel; Danny Mollerup Sørensen; Bob Asselbergh; Christine Klein; Stephan Zuchner; Albena Jordanova; Peter Vangheluwe; Ivailo Tournev; Rebecca Schüle
Journal:  Brain       Date:  2017-02       Impact factor: 13.501

3.  ATP13A2 deficiency disrupts lysosomal polyamine export.

Authors:  Sarah van Veen; Shaun Martin; Chris Van den Haute; Veronick Benoy; Joseph Lyons; Roeland Vanhoutte; Jan Pascal Kahler; Jean-Paul Decuypere; Géraldine Gelders; Eric Lambie; Jeffrey Zielich; Johannes V Swinnen; Wim Annaert; Patrizia Agostinis; Bart Ghesquière; Steven Verhelst; Veerle Baekelandt; Jan Eggermont; Peter Vangheluwe
Journal:  Nature       Date:  2020-01-29       Impact factor: 49.962

4.  Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion.

Authors:  Rossella Spataro; Maria Kousi; Sali M K Farhan; Jason R Willer; Jay P Ross; Patrick A Dion; Guy A Rouleau; Mark J Daly; Benjamin M Neale; Vincenzo La Bella; Nicholas Katsanis
Journal:  Hum Genomics       Date:  2019-04-16       Impact factor: 4.639

5.  ATP13A2 protects dopaminergic neurons in Parkinson's disease: from biology to pathology.

Authors:  Tao Dang; Wen-Jing Cao; Rong Zhao; Ming Lu; Gang Hu; Chen Qiao
Journal:  J Biomed Res       Date:  2022-03-28

6.  Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2.

Authors:  Shaun Martin; Sarah van Veen; Tine Holemans; Seyma Demirsoy; Chris van den Haute; Veerle Baekelandt; Patrizia Agostinis; Jan Eggermont; Peter Vangheluwe
Journal:  Parkinsons Dis       Date:  2016-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.